Jim Kiles, age 62, is the Founder of Ystrategies, a consulting firm providing investment, development and strategic support for technology platforms. In this role, Jim helps start-ups validate markets, identify customers and build their businesses. Jim is a member of the Lawrence Livermore National Laboratory Industrial Advisory Board and an Instructor for the Dept. of Energy's LabCorps program working with scientists from all of the US National Labs in their efforts to commercialize intellectual property targeting energy efficiency and renewable energy. Jim also takes active roles in emerging private start-ups and is Managing Director of GroundControl Solutions, Inc. and SAFE-Skills, LLC, two NY based technology businesses. Jim has been a Managing Director at Intel Capital (INTC) where he invested in numerous early stage technology companies.
$AMRS "In our first collaboration, Amyris developed technology capable of creating microbial strains to produce artemisinic acid — a precursor of artemisinin, an effective anti-malarial drug. The Malaria Challenge
Malaria is a preventable disease that affects over a quarter of a billion people and claims the lives of hundreds of thousands of people every year, mostly children under the age of five in Africa. In addition to its debilitating impact on the health of populations in developing countries, malaria has also been shown to be a major constraint to economic development.
Malaria patients can be treated with highly effective Artemisinin-based Combination Therapies (ACTs), but cultivating and extracting artemisinin, which comes from the Chinese Sweet Wormwood plant, is expensive and time-consuming. Lack of access to this vital compound prevents millions of people in the developing world from receiving critical ACTs. Semi Synthetic Artemisinin Process The Artemisinin Project
Amyris first developed and applied our technology to create microbial strains that produce artemisinic acid, a precursor of artemisinin, a highly effective anti-malarial therapeutic. This work was funded by a grant awarded from the Bill & Melinda Gates Foundation via OneWorld Health (now PATH’s Drug Development Program).
Amyris is working to ensure access to affordable malaria treatments worldwide. In 2008, Amyris made available its Artemisinic Acid-producing yeast strains to Sanofi, via OneWorld Health, on a royalty-free basis. Sanofi began using this technology at large-scale to produce Artemisinin for ACT treatments with orginal plans to produce enough semi-synthetic Artemisinin for up to 150 million treatments by 2014 and ensure distribution under a “no profit, no loss” principle.
In 2013, Amyris scientists, working with others in their field, detailed this major breakthrough in the scientific journal Nature. In the journal article, scientists describe how they engineered simple Baker’s yeast strains to produce never before seen concentrations of artemisinic acid, the key ingredient for making this cure for malaria. The details of this breakthrough in microbial engineering and process development can be found in the online version of Nature.
$MVES News Out The Movie Studio, Inc. Premiers Latest Feature Film Bad Actress for Worldwide Release at the 2016 American Film Market in Los Angeles, California
Marketwired October 25, 2016 HALLANDALE BEACH, FL--(Marketwired - Oct 25, 2016) - The Movie Studio, Inc. ( OTC PINK : MVES ) ("TMS" or the "Company"), www.TheMovieStudio.com is a vertically integrated motion picture production and distribution company with 18 completed motion pictures, 12 under acquisition, production and distribution assets. The Movie Studio is pleased to announce the premier of its latest feature film "BAD ACTRESS" www.badactressthemovie.com with exclusive worldwide distribution rights at the 37th edition of The American Film Market (AFM) www.americanfilmmarket.com in Los Angeles, California November 2nd - 9th 2016. The AFM is produced by Independent Film & Television Alliance (IFTA) and is the global trade association for the independent motion picture and television industry. Headquartered in Los Angeles, the organization represents more than 150 member companies from 23 countries, consisting of independent production and distribution companies, sales agents, television companies and financial institutions engaged in film finance. The American Film Market is attended by over 8,000 industry professionals, 1000 production Companies, 400 distributors and arranges over one billion in motion picture financing. The Movie Studio is excited about the premier of BAD ACTRESS and having the movie join the "BAD" movie genre: BAD TEACHER -- http://www.sonypictures.com/movies/badteacher/ -- $200 mm Worldwide BAD GRANDPA -- http://www.imdb.com/title/tt3063516/ -- $160 mm Worldwide BAD MOM -- http://stxmovies.com/badmoms/ -- $179 mm Worldwide BAD SANTA -- http://www.miramax.com/movie/bad-santa/ -- $77 mm Worldwide BAD SANTA 2 -- http://www.badsanta2.com -- COMING SOON! In Theaters November 23rd 2016
"The premier release of 'BAD ACTRESS' at AFM the timing could not be better with the Video on Demand (VOD) market being driven by title, genre or star. Following the locomotive Blockbusters in the BAD genre, 'BAD ACTRESS' could produce significant distribution interest. The Movie Studio's formula of developing vertically integrated sponsors, locations and product placements that create substantial production value in contrast with the true capital expenditures of the movie, could monetize the asset in both foreign and domestic markets," Gordon Scott Venters, the President and CEO of The Movie Studio, announced today.
TVOG's M & A program about to launch. To get in on a fully reporting stock under 2 cents with an 80 M OS that could be doing deals of $50 M or more? Awesome opportunity imo. They are now issuing full filings, are fully compliant, and 8ks are being put out as of today. This was the last step before they start announcing their deals.
For example, look at this pr from last month. They are looking to get into the hemp cafe market with up to 300 stores doing $1 M in revenues each. That is crazy money and makes this a dollar stock alone just based on that deal.
$ACOL Acology Inc. executives announced today that they are expanding their Canadian operations in anticipation of the national referendum to legalize recreational cannabis.
Recent high-level meetings with industry insiders have convinced Acology executives that the timing for increasing an already strong presence in the Canadian medical cannabis industry is in its' and their investor's best interest.
SDVI announced expected revenues of $4,443,000 for 2017 so if we use a multiple of 10 times revenues thats gives you a market cap of $44,430,000 and if you divide that by the shares outstanding it means SDVI should be trading at .0167 cents currently.
SDVI announced expected revenues of $17,240,000 for 2018 so if we use a multiple of 10 times revenues thats gives you a market cap of $172,400,000 and if you divide that by the shares outstanding it means SDVI should be trading at .065 cents longer term.
Also: $MVTG calm before the Storm 2.0 hits! Ask is thin and ready to break out over .02/share. Ultra Low float (65 Mil), low OS (144 Mil), undervalued, GE is their new partner, fully SEC reporting since the IPO in 2008. Huge news pending. 5 week rally already underway. No sellers left!
$MVTG speaking of things I can't even make up today here is some good $MVTG science and engineering primer info on fisher tropsch technology that will be the second stage of the MVTG-GE-ERC-SynGas reactor that makes syn gas out of captured waste CO2 carbon dioxide. GE is their partner now since GE bought Alstom.
THE $MVTG ERC will use CO2 instead of coal, and solar or wind electric power directly to make the H2 and CO products cleanly and efficiently with no coal toxic waste products and no CO2 byproduct waste.
The Fischer-Tropsch process is a catalytic chemical reaction in which carbon monoxide (CO) and hydrogen (H2) in the syngas are converted into hydrocarbons of various molecular weights according to the following equation:
(2n+1) H2 + n CO ? Cn H(2n+2) + n H2O
Where n is an integer. Thus, for n=1, the reaction represents the formation of methane, which in most CTL or GTL applications is considered an undesirable byproduct. The Fischer-Tropsch process conditions are usually chosen to maximize the formation of higher molecular weight hydrocarbon liquid fuels which are higher value products.
Depending on the catalyst, temperature, and type of process employed, hydrocarbons ranging from methane to higher molecular paraffins and olefins can be obtained. The Fischer-Tropsch synthesis reaction, in theory, is a condensation polymerization reaction of CO. Its products obey a well-defined molecular weight distribution according to a relationship known as Shultz-Flory distribution.
In layman's language it can make synthetic diesel fuel out of syngas!!!!
It is already commercially viable and has been since the Germans invented it back before WWII.
But today's syn gas is made from burning and reforming Natural gas making tons of waste CO2 in the process.
$FUSZ - Cast Your Votes! Where will this Supernova Stock settle once the @Oracle and @marketo News Hits later this month at the @Oracle Netsuite SuiteWorld 2018 and @marketo Marketing Nation Summit?
Southern Eagle is the first Anheiser Busch partner for APRU. They are selling APRU's products in Southeast. The goal is to offer APPLE RUSH products nationally through other Anheiser Busch connections!
$SAGD>>> had 200m OS reduction news Monday, bringing it down to about 500m, and 2 pending acquisitions in MMJ as well as a crypto venture we are waiting to hear an update on
$IVST Huge News Just Out Innovest Global Signed LOI to Acquire Midwest Curtainwalls, a $12 Million Revenue and Profitable Business
CLEVELAND, Ohio, Oct. 29, 2018 (GLOBE NEWSWIRE) -- Innovest Global Inc. (OTC Markets: IVST) (the “Company” or “Innovest”), a conglomerate with operations in commercial and industrial products and services, energy, biotechnology, and health services, details today that it signed a Letter of Intent to acquire Midwest Curtainwalls (“Midwest”).
Midwest is a company that will add to our Construction and Building Materials efforts. They generate $10-$12 million in annual revenue from specialty commercial construction contracts, with projections of $2.4 million in profit from current contracts. This acquisition will mark the most profitable IVST acquisition to date, and is contingent upon due diligence and final documentation.
John Yenges is a Six Sigma trained construction executive who recently became their Chief Operating Officer. With this transaction, Innovest will promote Mr. Yenges to president of Midwest, which he will continue to run. Mr. Yenges has demonstrated that he has a history of providing rapid growth to companies he joins, and a pipeline of relational opportunities, which Innovest believes will provide Midwest significant potential for similar growth.
Midwest (click here for their website) has been in business since 1959 and is an industry leader. Their work has international appeal having done major projects in the United States, Barcelona Spain, London England, and Hong Kong.
The LOI outlines a transaction, which is primarily a stock exchange, and is commensurate with recent Innovest acquisition structures. We expect to issue approximately 2 million restricted common IVST shares to the seller. Closing is contingent upon a variety of items including due diligence and acceptable final documentation.
About Innovest Global, Inc.
Innovest Global, Inc. (OTC Markets: IVST) is conglomerate with operations in commercial and industrial products and services, energy, biotechnology, and health services. Our primary growth strategy is to acquire existing companies in a select few industries, and attract new customers in cost effective ways. Currently, we have a Commercial & Industrial Division, a Biotechnology & Health Services Division, and our new Construction & Building Materials Division.
For more information, please visit: http://www.innovestglobal.com, and follow us on Twitter and Facebook @innovestglobal.
Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts included in this press release are forward-looking statements. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Investors should not place any undue reliance on forward-looking statements since they involve known and unknown, uncertainties and other factors which are, in some cases, beyond the Company's control which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to operations, results of operations, growth strategy and liquidity. Such risks, uncertainties and other factors, which could impact the Company and the forward-looking statements contained herein are included in the Company's filings with the OTC Markets. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future.
Contact Information Corporate Office: (216) 815-1122 info@innovestglobal.com Twitter @innovestglobal
Investor Relations: Hayden IR (917) 658-7878 hart@haydenir.com